CN-117241814-B - Combination of myrtle extract and tripterygium wilfordii extract for controlling inflammation caused by propionibacterium acnes

Abstract

The present invention relates to a combination comprising myrtle extract and tripterygium wilfordii extract, in particular for the treatment of inflammation caused by propionibacterium acnes and for the treatment of acne skin.

Inventors

• S. Besson Tangya
• L. Garidu
• C. Mias

Assignees

• 皮埃尔·法布尔皮肤化妆品公司

Dates

Publication Date

20260512

Application Date

20220310

Priority Date

20210310

Claims (15)

1. 1. A cosmetic or dermatological combination of 0.08% to 0.2% by weight of a dry myrtle extract relative to the total weight of the composition and 0.2% to 0.4% by weight of a dry myrtle extract relative to the total weight of the composition, wherein the myrtle extract is a non-polar fraction comprising myrtle phloroglucinol and ursolic acid, the myrtle extract comprising at least one pentacyclic triterpene selected from the group consisting of euonymus triterpene a, euonymus triterpene B, tripterine and mixtures thereof, wherein the myrtle extract is obtained by extraction of leaves of myrtle using isopropyl acetate, wherein the myrtle extract is obtained by the following method: (i) The proliferation stage of the tripterygium wilfordii cells in the proliferation culture medium, (Ii) An induction stage by adding to the cell culture obtained in step (i) an induction mixture comprising at least one monocarboxylic acid compound inducer and at least one biological inducer, and (Iii) Preparing an extract comprising pentacyclic triterpene using the cell culture obtained in step (ii).
2. 2. The cosmetic or dermatological combination of claim 1, wherein the myrtle phloroglucinol comprises myrtle phloroglucinol A, B', D, B, isophthaloyl phloroglucinol, and semi-myrtle phloroglucinol.
3. 3. Cosmetic or dermatological combination according to claim 1, characterized in that the total content of phloroglucinol is 3% to 10% by weight relative to the total weight of the dry myrtle extract.
4. 4. Cosmetic or dermatological combination according to claim 1, characterized in that the content of ursolic acid is between 10% and 30% by weight with respect to the total weight of the dry myrtle extract.
5. 5. The cosmetic or dermatological combination according to claim 1, characterized in that the total content of myrtle phloroglucinol is 3 to 10% by weight relative to the total weight of the dry myrtle extract, the content of ursolic acid is 10 to 30% by weight relative to the total weight of the dry myrtle extract, and the myrtle phloroglucinol comprises myrtle phloroglucinol A, B', D, B, isophthaloyl and semi-myrtle phloroglucinol.
6. 6. The cosmetic or dermatological combination of claim 1, wherein the tripterygium extract comprises euonymus triterpene a, euonymus triterpene B, and celastrol.
7. 7. Cosmetic or dermatological combination according to claim 1, characterized in that the thunder god vine extract comprises 90% by weight of at least one pentacyclic triterpene with respect to the total weight of the dry extract.
8. 8. The cosmetic or dermatological combination according to claim 1, wherein the tripterygium extract comprises from 1% to 20% by weight of euonymus triterpene a relative to the total weight of the dry extract, from 1% to 20% by weight of euonymus triterpene B relative to the weight of the dry extract, and at least 60% by weight of tripterine relative to the total weight of the dry extract.
9. 9. The cosmetic or dermatological combination according to claim 1, wherein the myrtle extract is a non-polar fraction comprising myrtle phloroglucinol and ursolic acid, wherein the total content of myrtle phloroglucinol is from 3% to 10% by weight relative to the total weight of the dry myrtle extract, and the content of ursolic acid is from 10% to 30% by weight relative to the total weight of the dry myrtle extract, wherein the myrtle phloroglucinol comprises myrtle phloroglucinol A, B', D, B, isophthalol and semiamyrtle phloroglucinol, and Wherein the Tripterygium wilfordii extract comprises 1% to 20% by weight of euonymus triterpene A relative to the total weight of the dry extract, 1% to 20% by weight of euonymus triterpene B relative to the weight of the dry extract, and at least 60% by weight of celastrol relative to the total weight of the dry extract.
10. 10. Use of a cosmetic or dermatological combination according to any one of claims 1 to 9, for the preparation of a cosmetic or dermatological composition for the treatment of inflammation caused by propionibacterium acnes.
11. 11. Use of a cosmetic or dermatological combination according to any one of claims 1 to 9 for the preparation of a cosmetic or dermatological composition for treating acne-prone skin.
12. 12. Cosmetic or dermatological composition consisting of a cosmetic or dermatological combination according to any one of claims 1 to 9 and at least one cosmetically or dermatologically acceptable excipient.
13. 13. The composition of claim 12, wherein the composition is in a form suitable for topical administration.
14. 14. Use of a composition according to claim 12 in the manufacture of a medicament for the treatment of inflammation caused by propionibacterium acnes.
15. 15. Use of a composition according to claim 12 in the manufacture of a medicament for the treatment of acne-prone skin.

Description

Combination of myrtle extract and tripterygium wilfordii extract for controlling inflammation caused by propionibacterium acnes Technical Field The present invention relates to a novel combination comprising myrtle extract and tripterygium wilfordii (Tripterygium wilfordii) extract and compositions comprising the combination, in particular for use in the field of acne, in particular for use in the treatment of inflammation caused by propionibacterium acnes (c.acnes). Background Acne is a common multifactorial skin disorder of hair follicles and sebaceous glands, which can lead to the formation of comedones, infecting the face, the scapular region, the arms and the intertrigo region. It is the most common major cause of skin diseases. It is important not to light the disease and treat it properly, as it may produce disabling socioeconomic consequences, especially due to scar formation. There are various forms of acne, all of which are common factors in the attack of sebaceous gland follicles. For example, these acne include acne vulgaris, acne conglobata, acne keloids from the neck, drug acne, recurrent follicular acne, necrotic acne, neonatal acne, premenstrual acne, occupational acne, senile acne, and solar acne. Acne vulgaris or acne vulgaris, also known as adolescent polymorphic acne, is the most common and comprises four phases: Stage 1 corresponds to acne type, characterized by a large number of open and/or closed comedones and micro-cysts; stage 2 or papulopustular acne is of mild to moderate severity, characterized by the presence of open and/or closed comedones, micro-cysts and red papules and pustules. It mainly infects the face and leaves some scar; Stage 3 or papular acne is more severe, extending to the back, chest and shoulders. It is accompanied by a large amount of scarring; Stage 4 or nodulocystic acne is accompanied by a substantial amount of scarring. It appears as a nodule and a very large and painful purple pustule. Acne affects almost all people in the lightest form. Its frequency of appearance is highest in puberty, but it may first appear at ages 7 to 9 years and above 40 years. Acne is still frequent after age 25. In addition, acne affects both men and women equally. During adolescence, the effects of hormone secretion, in particular androgens, and in addition to various external factors, excessive sebum production, known as sebum hypersecretion, is observed. In subjects susceptible to acne, this environment favors the growth of the predominant acne bacteria, propionibacterium acnes (Cutibacterium acnes, c.acnes) (previously referred to as Propionibacterium acnes). This bacterium metabolizes skin triglycerides into stimulatory fatty acids by lipase attack of the hair follicle wall and surrounding dermis, also produces chemoattractants for various enzymes and immunophagocytes, and stimulates various types of cells (particularly sebocytes, keratinocytes, and monocytes) to produce pro-inflammatory cytokines that exacerbate inflammation. Against this bacterial species has long been considered an important point in the treatment of acne. Various topical antibacterial agents have been used widely up to now (benzoyl peroxide, erythromycin, triclosan). However, recently, researchers have appreciated that the goal should not be to eradicate propionibacterium acnes (which is essential for tissue homeostasis) as a symbiotic bacteria, but to reestablish balance, as acne is associated with a loss of diversity of propionibacterium acnes germ line, with pathogenic germ line IA1 predominating. Contrary to what has long been considered, acne is not related to the proliferation of propionibacterium acnes, but to the change in the proportions of the germ types and the loss of richness of these germ types. Similarly, chronic systemic antibiotic therapy is sometimes combined with therapy to a greater or lesser extent (tetracycline, doxycycline) depending on the severity of the condition. Now, dermatologists are increasingly turning to topical anti-inflammatory agents and sebum regulators. All of these treatments have been observed to fail frequently, typically because of the large proportion of resistant strains of propionibacterium acnes. This resistance may be the result of the organization of the bacterial population into biofilms. Biofilms are bacterial cell populations contained in the extracellular matrix secreted by microorganisms, are composed of sugar polymers and are referred to as glycogens. Sessile bacteria (associated with biofilms) are phenotypically and physiologically distinct from planktonic (free) bacteria. Studies have demonstrated the ability of propionibacterium acnes to form biofilms equally well in vitro as in vivo (Holmberg et al, clin. Microbiol. Select. 2009,15, 787-795) and on medical devices (Craig et al, j. Am. Acad. Dermatol.2007, 722-724). This bacterium plays a key role in acne, particularly by stimulating a local inflammatory response (Dagnelie et al, journal of the Europ